Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Test to Quantify NOTCH Pathway Activity in T Cell Acute Lymphoblastic Leukemia Patients

Kirsten Canté-Barrett, PhD, Laurent Holtzer, PhD, Henk van Ooijen, PhD, Rico Hagelaar, Valentina Cordo', MSc, Wim Verhaegh, PhD, Anja van de Stolpe, MD PhD, Jules P.P. Meijerink, PhD

Blood (2019) 134 (Supplement_1): 4661.

https://doi.org/10.1182/blood-2019-122856

Published: 2019

Journal Articles

T-ALL Oncogenes Function in the Context of Pre- and Post T-Cell Commitment Programs

Kirsten Canté-Barrett, PhD, Eric Vroegindeweij, PhD, Yunlei Li, PhD, Hans Clevers, MD PhD, Jules Meijerink, PhD

Blood (2017) 130 (Supplement 1): 3806.

https://doi.org/10.1182/blood.V130.Suppl_1.3806.3806

Published: 2017

Journal Articles

T-Cell Acute Lymphoblastic Leukemia Patients with Mutations in IL7Ra or Downstream RAS-MEK or PI3K-AKT Can be Collectively Targeted By Combination of RAS and AKT Inhibitors

Kirsten Canté-Barrett, PhD, Jill AP Spijkers-Hagelstein, Jessica GCAM Buijs-Gladdines, Wilco K Smits, Rogier C Buijsman, PhD, Guido JR Zaman, PhD, Rob Pieters, MD PhD, Jules PP Meijerink, PhD

Blood (2015) 126 (23): 445.

https://doi.org/10.1182/blood.V126.23.445.445

Published: 2015

Journal Articles

Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia

Eric M Vroegindeweij, PhD, Tim Lammens, PhD, Erik Splinter, PhD, Anne Uyttebroeck, Kirsten Canté-Barrett, PhD, Jessica GCAM Buijs-Gladdines, Wilco K Smits, Peter Vandenberghe, MD PhD, Max J van Min, PhD, Rob Pieters, MD PhD, Pieter Van Vlierberghe, PhD, Jules PP Meijerink, PhD

Blood (2015) 126 (23): 1409.

https://doi.org/10.1182/blood.V126.23.1409.1409

Published: 2015

Journal Articles

Constitutive Expression of MEF2C, LYL1, or LMO2 in CD34 + HSCs Blocks the in Vitro Differentiation before the T-Cell Commitment Point and Could be Oncogenic in Early T-Cell Progenitor ALL

Kirsten Canté-Barrett, PhD, Rui D Mendes, Wilco K Smits, Rob Pieters, MD PhD, Jules PP Meijerink, PhD

Blood (2015) 126 (23): 2423.

https://doi.org/10.1182/blood.V126.23.2423.2423

Published: 2015

Journal Articles

3D Modeling of Novel Transforming JAK Mutations in T-Cell Acute Lymphoblastic Leukemia Reveals Altered Pseudokinase-Kinase Domain Interactions That Result in Constitutive JAK Kinase Activity

Kirsten Canté-Barrett, PhD, Joost CM Uitdehaag, PhD, Jessica GCAM Buijs-Gladdines, Wilco K Smits, Rogier C Buijsman, PhD, Guido JR Zaman, PhD, Rob Pieters, MD PhD, Jules PP Meijerink, PhD

Blood (2015) 126 (23): 869.

https://doi.org/10.1182/blood.V126.23.869.869

Published: 2015

NARROW

A Test to Quantify NOTCH Pathway Activity in T Cell Acute Lymphoblastic Leukemia Patients

T-ALL Oncogenes Function in the Context of Pre- and Post T-Cell Commitment Programs

T-Cell Acute Lymphoblastic Leukemia Patients with Mutations in IL7Ra or Downstream RAS-MEK or PI3K-AKT Can be Collectively Targeted By Combination of RAS and AKT Inhibitors

Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia

Constitutive Expression of MEF2C, LYL1, or LMO2 in CD34 + HSCs Blocks the in Vitro Differentiation before the T-Cell Commitment Point and Could be Oncogenic in Early T-Cell Progenitor ALL

3D Modeling of Novel Transforming JAK Mutations in T-Cell Acute Lymphoblastic Leukemia Reveals Altered Pseudokinase-Kinase Domain Interactions That Result in Constitutive JAK Kinase Activity

Email alerts

ASH Publications

American Society of Hematology

A Test to Quantify NOTCH Pathway Activity in T Cell Acute Lymphoblastic Leukemia Patients

T-ALL Oncogenes Function in the Context of Pre- and Post T-Cell Commitment Programs

T-Cell Acute Lymphoblastic Leukemia Patients with Mutations in IL7Ra or Downstream RAS-MEK or PI3K-AKT Can be Collectively Targeted By Combination of RAS and AKT Inhibitors

Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia

Constitutive Expression of MEF2C, LYL1, or LMO2 in CD34 + HSCs Blocks the in Vitro Differentiation before the T-Cell Commitment Point and Could be Oncogenic in Early T-Cell Progenitor ALL

3D Modeling of Novel Transforming JAK Mutations in T-Cell Acute Lymphoblastic Leukemia Reveals Altered Pseudokinase-Kinase Domain Interactions That Result in Constitutive JAK Kinase Activity

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only